Article Information
- Received January 28, 2021
- Revision received April 6, 2021
- Accepted April 12, 2021
- Published online April 23, 2021.
Author Information
Author contributions
Author contributions: D.J., Y.K., and J.C. designed research; D.J., Y.K., and R.R. performed research; D.J. and Y.K. analyzed data; D.J., Y.K., and J.C. wrote the paper.
↵* D.J. and Y.K. contributed equally to this work.
Disclosures
J.C. has received honoraria, consulting fees, and/or grant support from Celgene, Arena Pharmaceuticals, Ono Pharmaceuticals and Novartis. All other authors declare no competing financial interests.
This work was supported by non-federal funds from Novartis (J.C.). This work was also supported by the National Institutes of Health/National Institute of Neurological Disorders and Stroke Grant R01NS103940 and postdoctoral fellowships to Y.K. (The Uehara Memorial Foundation, the Kanae Foundation for the Promotion of Medical Science, Mochida Memorial Foundation for Medical and Pharmaceutical Research, and the Human Frontier Science Program).
Funding
HHS | NIH | National Institute of Neurological Disorders and Stroke (NINDS)
R01NS103940Novartis Pharmaceuticals Corporation (NPC)
Other Version
- You are viewing the most recent version of this article.
- previous version (April 23, 2021).
Article usage
In this issue
